Navigation path

SAGhE

Safety and Appropriateness of Growth hormone treatments in Europe

back home
Print version Increase text Decrease text

Approximately 40 000 children are treated with daily injections of growth hormone (GH) in the EU. GH efficacy is undisputed in severe GH deficiency but is more limited in other situations. The possibility has been raised that GH use in childhood might increase the risk of cancer later in life but little data is available. SAGhE will evaluate the impact of GH treatment on height, psychosocial status as well as long-term mortality and cancer incidence in a large unbiased metacohort of patients. The data will then be integrated and disseminated to several levels of users. SAGhE is unique worldwide in its design, size and potential to answer important questions raised on childhood GH treatments.

Coordinator:
Prof. Jean-Claude Carel
Endocrinologie Diabétologie Pédiatrique & INSERM U690
Université Paris 7 Denis Diderot
Paris, France
jean-claude.carel@inserm.fr
EC contribution: EUR 2 989 154
Duration: 36 months
Starting date: 01/06/2009
Project web-site: http://saghe.aphp.fr/site/spip.php/